H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as Well as Other Newly Diagnosed HLA-A2+ H3.3K27M Positive Gliomas
Latest Information Update: 26 Feb 2024
At a glance
- Drugs Cancer vaccine (Primary) ; Nivolumab (Primary) ; Poly ICLC; Tetanus toxoid
- Indications Diffuse intrinsic pontine glioma; Glioma
- Focus Adverse reactions; Therapeutic Use
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 11 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 10 Nov 2021 Planned End Date changed from 1 Jan 2023 to 30 Nov 2024.